Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment Diamyd Medical has entered into financing agreements with U.S. investors totaling $125 million and announced full enrollment in its Phase 3 trial.

Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment #Sweden #Stockholm #Diamyd_Medical #Phase_3_Trial #retogatein

Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion Diamyd Medical announces successful financing agreements totaling $125 million and the completion of its Phase 3 clinical trial for Type 1 diabetes.

Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion #Sweden #Stockholm #Diamyd_Medical #Phase_3_Trial #retogatein

GC Biopharma Initiates Phase 3 Clinical Trial for BARYCELA Vaccine in Thailand GC Biopharma has submitted an IND for a Phase 3 trial of BARYCELA, a varicella vaccine, aiming for approval in Southeast Asia by 2027.

GC Biopharma Initiates Phase 3 Clinical Trial for BARYCELA Vaccine in Thailand #South_Korea #GC_Biopharma #Yongin #Phase_3_Trial #BARYCELA

Moleculin Biotech Strengthens Global Patent Portfolio for Annamycin, Aiming for Next-Gen Cancer Treatment Moleculin Biotech has secured additional patent allowances for Annamycin, aiming to enhance its global exclusivity and expedite clinical trials for cancer therapies.

Moleculin Biotech Strengthens Global Patent Portfolio for Annamycin, Aiming for Next-Gen Cancer Treatment #USA #Houston #Moleculin_Biotech #Annamycin #Phase_3_Trial